Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance.
Ontology highlight
ABSTRACT: Mutations and gene amplifications that confer drug resistance emerge frequently during chemotherapy, but their mechanism and timing are poorly understood. Here, we investigate BRAFV600E amplification events that underlie resistance to the MEK inhibitor selumetinib (AZD6244/ARRY-142886) in COLO205 cells, a well-characterized model for reproducible emergence of drug resistance, and show that BRAF amplifications acquired de novo are the primary cause of resistance. Selumetinib causes long-term G1 arrest accompanied by reduced expression of DNA replication and repair genes, but cells stochastically re-enter the cell cycle during treatment despite continued repression of pERK1/2. Most DNA replication and repair genes are re-expressed as cells enter S and G2; howe
SUBMITTER: Channathodiyil P
PROVIDER: S-EPMC9575185 | biostudies-literature | 2022 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA